不同胰升血糖素样肽1受体激动剂类药物心血管结局研究差异及其在临床治疗中的指导意义  

Similarities and differences of GLP-1 RA cardiovascular outcome trials and their significance in clinical practice

作　　者：杨文嘉[1] 刘思颖 纪立农[1] YANG Wenjia;LIU Siying;JI Linong(Department of Endocrinology,Peking University People’s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院内分泌科,100044 [2]礼来苏州制药有限公司

出　　处：《中国糖尿病杂志》2021年第3期233-240,共8页Chinese Journal of Diabetes

摘　　要：动脉粥样硬化性心血管疾病(ASCVD)是T2DM患者重要的伴发疾病和主要死因。在DM新药研发规则的影响下,新型DM药物的心血管结局研究(CVOT)数据不断涌现。7项针对胰升血糖素样肽1受体激动剂(GLP-1 RA)类药物的CVOT,因研究目的不同,采用不同的研究设计来验证不同的科学假设,全面证明GLP-1 RA类药物心血管安全性的同时,显示出某些药物的心血管保护作用。GLP-1 RA类药物临床证据使其在DM管理中的地位上升,为DM患者高血糖管理和心血管疾病防治提供新的解决方案。Atherosclerotic cardiovascular disease(ASCVD)is an important concomitant disease and the leading cause of death in patients with type 2 diabetes mellitus(T2DM). Data from cardiovascular outcome trials(CVOT)of novel antidiabetic drugs booms due to regulatory requirements of the research and development of novel antidiabetic drugs. Seven published CVOTs of Glucagon-like peptide-1 receptor agonists(GLP-1 RA)comprehensively demonstrated cardiovascular safety of them and further indicated the cardiovascular protective effects of several GLP-1 RAs by applying different decigns to validate different hypotheses. All these newly obtained clinical evidence has raised the status of GLP-1RA in diabetes management and provided new solutions for hyperglycemia management,prevention and treatment for cardiovascular diseases in patients with diabetes.

关 键 词：糖尿病 2型 心血管结局研究 胰升血糖素样肽1受体激动剂 心血管安全性 

分 类 号：R587.2[医药卫生—内分泌] R543.5[医药卫生—内科学]